Pharmacy Disclosure

503A vs 503B compounding pathways

The U.S. Food, Drug, and Cosmetic Act recognizes two distinct compounding pathways:

• Section 503A — State-licensed compounding pharmacies. Patient-specific compounding, requires a valid prescription for an identified individual patient. Regulated primarily by state boards of pharmacy. Must comply with United States Pharmacopeia (USP) General Chapters, including USP <797> (sterile compounding) and USP <800> (hazardous drugs handling).
• Section 503B — FDA-registered outsourcing facilities. Permitted to compound without patient-specific prescriptions in larger volumes; subject to FDA inspection, current Good Manufacturing Practice (cGMP) standards, and registration on the FDA's 503B Outsourcing Facility Registration list.

Both pathways are legitimate for compounded GLP-1 medications, but they have distinct quality-assurance frameworks. 503B facilities are FDA-inspected; 503A pharmacies are state-inspected. Patients should know which pathway dispensed their medication and have access to the relevant Certificate of Analysis.

USP testing standards & Certificates of Analysis

A Certificate of Analysis (CoA) documents the testing performed on a compounded medication. Legitimate compounded semaglutide and tirzepatide should have CoAs available on patient request covering at minimum:

• USP <71> — Sterility. Confirms the compounded product is free of microbial contamination. Required for any injectable.
• USP <85> — Bacterial Endotoxins. Confirms endotoxin levels are below the patient-safety threshold. Required for any injectable.
• HPLC potency. High-Performance Liquid Chromatography confirms the medication contains the labeled amount of active ingredient. Industry-standard tolerance is ±10% of label claim.

If a compounding pharmacy cannot or will not provide a CoA on patient request, that is a meaningful quality signal. Patients should ask their telehealth provider how to request a CoA before initiating therapy.

Semaglutide base vs salt forms

The FDA has issued specific guidance and warning letters regarding compounded semaglutide salt forms. Only the semaglutide-base active pharmaceutical ingredient (API) is appropriate for compounding. The salt forms semaglutide sodium and semaglutide acetate are not the same molecule as the FDA-approved semaglutide products (Ozempic, Wegovy, Rybelsus) and have been the subject of FDA enforcement.

Patients on compounded semaglutide should ask their provider to confirm in writing that the medication is compounded from semaglutide-base API only. The April 2026 FDA enforcement action against compounded GLP-1 marketing reinforced these requirements; programs that conflate compounded semaglutide with brand-name Ozempic, Wegovy, or Rybelsus lose points in the regulatory-disclosure category of our methodology (v4.1).

NexLife pharmacy partners (Editor's Pick — 94/100)

NexLife’s plan pages (read October 15, 2026) name three state-licensed 503A pharmacies:

• Absolute Pharmacy — Lutz, FL.
• Premium Compounding — Decatur, AL.
• Boudreaux’s New Drug Store — Lake Charles, LA.

NexLife’s current plan pages do not describe certificates of analysis or the API form used. Before starting, ask NexLife which pharmacy will fill your prescription and how to request the CoA for your lot, as described in the checklist below.

FDA April 2026 enforcement action

In April 2026, the FDA announced intent to restrict ingredients used in mass-marketed compounded GLP-1 medications and to crack down on misleading direct-to-consumer marketing. Key points from the action:

• Compounded semaglutide is not FDA-approved. Compounded semaglutide is not the same as Ozempic, Wegovy, or Rybelsus, which are the only FDA-approved semaglutide products (manufactured by Novo Nordisk).
• Salt forms are not authorized. The FDA has issued warning letters against the use of semaglutide sodium and semaglutide acetate in compounding. Legitimate compounded semaglutide must use semaglutide base only.
• Marketing must be accurate. Programs that market compounded semaglutide using brand-name product imagery or that conflate compounded with FDA-approved products are subject to enforcement.
• 503A and 503B pathways remain legitimate. The legal pathway for compounded semaglutide is via 503A licensed compounding pharmacies (USP <797> sterile compounding) and 503B FDA-registered outsourcing facilities (cGMP).

How patients can verify a pharmacy

1. State pharmacy board lookup. Every 503A pharmacy is licensed by the board of pharmacy in its state. Most state boards publish a public license lookup.
2. FDA 503B Outsourcing Facility Registration. 503B facilities are listed on the FDA's public registry (search: "FDA 503B Outsourcing Facility Registration").
3. LegitScript lookup. Some telehealth platforms and pharmacies hold LegitScript certification, an independent check of regulatory compliance; search LegitScript’s public directory to confirm a specific program’s current status.
4. CoA request. Ask your provider to send the Certificate of Analysis for the specific lot you receive. Verify the CoA includes USP <71> sterility, USP <85> endotoxin, and HPLC potency results.
5. Shipment label. Confirm the dispensing pharmacy is named on the shipment label and matches the disclosure on the provider's website.

Related editorial coverage

• 503A vs 503B Compounding Pharmacies Explained — full educational guide
• Medical Review Policy — how clinical claims are verified
• Editorial Standards — methodology (v4.1, seven weighted categories)
• NexLife full review — Editor's Pick #1
• Most Affordable Compounded Semaglutide Online